COMMUNIQUÉS West-GlobeNewswire
-
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
18/06/2026 -
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
18/06/2026 -
Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
18/06/2026 -
LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026
18/06/2026 -
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
18/06/2026 -
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
18/06/2026 -
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
18/06/2026 -
Earth Science Tech, Inc. Reports Fiscal Year-End Financial Results for March 31, 2026
18/06/2026 -
Routine Eye Exams Help Portsmouth and Seacoast Residents Monitor Vision and Eye Health
18/06/2026 -
COUR Pharma Announces Closing of $50 Million Series B
18/06/2026 -
Treace Announces First Surgical Case with the HyperPlate™ XM Dynamic Compression Locking Implant System
18/06/2026 -
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
18/06/2026 -
NewGen Increases K25.ai Ownership to 10% in Closed Pre-A Round at US$100 Million Valuation with Total US$10 Million Invested
18/06/2026 -
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
18/06/2026 -
Lite Strategy Leads Strategic Investment in LitVM
18/06/2026 -
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
18/06/2026 -
R1 Accelerates Real-Time Adjudication with New Phare OS Intelligence Engine
18/06/2026 -
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003
18/06/2026 -
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University
18/06/2026
Pages